Melanotan 1 (Afamelanotide)

What Is Melanotan 1?

Melanotan 1, also known as afamelanotide in its regulated pharmaceutical form, is a synthetic analog of alpha-melanocyte-stimulating hormone.

It is studied for increasing eumelanin production through melanocortin-1 receptor activation. This gives it relevance in pigmentation biology and light-sensitivity research.

Afamelanotide has an approved medical role for erythropoietic protoporphyria in some regions, but that regulated implant is distinct from informal research-compound discussions.

On Peptidelogy, Melanotan 1 is organized as a research reference rather than a consumer product page. The most useful way to read the entry is to separate chemical identity, proposed mechanism, study context, safety observations, and unresolved questions.

This matters because many peptide topics are discussed online with a mix of laboratory data, clinical studies, anecdotal claims, and supplier language. A reliable reference keeps those categories separate so readers can see what has actually been studied and what remains speculative.

What Does Melanotan 1 Do?

Research discussions of Melanotan 1 usually center on melanogenesis, photoprotection, epp studies. In practice, that means studies look for measurable changes in defined biological pathways, tissue models, biomarkers, or clinical endpoints, depending on the compound.

The important distinction is that a studied effect is not the same as a recommendation or guaranteed outcome. Cell-culture findings, animal-model findings, and human trial findings carry different levels of evidence and cannot be treated interchangeably.

Mechanism of Action

Melanotan 1 activates MC1R on melanocytes. MC1R signaling increases eumelanin synthesis, which is the darker form of melanin associated with photoprotective pigmentation.

The compound is more selective than Melanotan 2 and is mainly discussed around pigmentation rather than the broader melanocortin effects associated with MT-2.

Mechanistic explanations are useful because they show why researchers are interested in Melanotan 1, but they should not be read as proof of real-world efficacy. A plausible pathway still requires well-designed experiments, appropriate controls, reproducible results, and safety evaluation.

Research & Studied Effects

Evidence interpretation

When reviewing studies on Melanotan 1, the study population or model is central. Findings from rodents, isolated cells, cosmetic panels, endocrine challenge tests, or late-stage clinical trials answer different questions. Stronger pages and citations make that context visible rather than flattening all research into a single claim.

The most reliable summaries also distinguish direct evidence on Melanotan 1 from evidence on related peptides, parent hormones, blend components, or broader drug classes. That distinction is especially important for combination blends and non-peptide compounds that are commonly grouped beside peptides online.

Dosage Information (Research Reference)

Research and clinical literature includes subcutaneous implant administration for afamelanotide in specific medical contexts.

This page does not provide administration instructions or convert approved-drug information into nonmedical use guidance.

Administration and reconstitution context

Some public pages discuss reconstitution, vial concentration, and route of administration. Peptidelogy does not turn those discussions into instructions. Where those details appear in literature, they are treated as study-method information tied to a specific protocol, not a general template.

Any dose reported for Melanotan 1 should be interpreted alongside route, species, participant criteria, duration, outcome measures, and safety monitoring. Removing those details can make a research dose look more broadly applicable than it is.

Side Effects & Safety Profile

• Research reports include nausea, headache, flushing, and implant-site effects.
• Increased pigmentation of freckles or moles has been observed, making dermatologic monitoring relevant in clinical contexts.

Safety summaries for Melanotan 1 are limited by the quality and maturity of the evidence. A compound with promising mechanistic data may still have unknown risks, and a compound studied clinically may still have indication-specific warnings, contraindications, or monitoring requirements.

Research Quality Notes

Reference pages in this category often include quality, handling, and source-vetting discussions. For Peptidelogy, those ideas are rewritten as research-quality cautions: identity, purity, storage stability, sterility where relevant, and documentation all affect whether a study can be interpreted reliably.

For defined peptides, useful documentation may include sequence confirmation, molecular-weight verification, batch-specific purity testing, and contaminant screening. For blends or branded formulation topics, the first question is whether the ingredient composition is standardized enough to compare one study or claim with another.

This section is not purchasing guidance and does not endorse any supplier. It is included because poor identity control, degradation, contamination, or unclear formulation can undermine research interpretation and create safety uncertainty.

Frequently Asked Questions

Melanotan 1 vs Melanotan 2

Related Peptides

References

1. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine. 2015;373(1):48-59.
2. Hadley ME, Dorr RT. Melanocortin peptide therapeutics. Peptides. 2006;27(4):921-930.
3. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Archives of Dermatology. 1988;124(6):869-871.